Skip to main content

Advertisement

Fig. 2 | BMC Cancer

Fig. 2

From: Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens

Fig. 2

Overall survival among patients with AML-MRC. a Overall survival for all patients with AML-MRC treated with azacitidine or CCR. b Sensitivity analysis, in which patients who switched to alternate therapy were censored at the time they did so. c Overall survival by NCCN cytogenetic risk. d Overall survival by age group

Back to article page